Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin, A Reanalysis of the Data

Marik et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001443
Sep 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
Updated meta analysis showing no significant change if Elgazzar et al. is excluded.
7 meta analyses show significant improvements with ivermectin for mortality Bryant, Hariyanto, Kory, Lawrie, Nardelli, Zein, hospitalization Schwartz, recovery Kory, and cases Kory.
Currently there are 103 ivermectin for COVID-19 studies, showing 49% lower mortality [35‑60%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 81% fewer cases [71‑87%].
Marik et al., 2 Sep 2021, peer-reviewed, 2 authors.
This PaperIvermectinAll
Abstract: Letters to the Editor e579 Queen Mary University of London London, United Kingdom The authors have no conflicts of interest to declare. REFERENCES 1. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021;28:e434–e460. 2. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of COVID-19: a systematic review and metaanalysis of randomized controlled trials.,Clin Infect Dis. 2021; ciab591. doi: 10.1093/cid/ciab591. 3. Crawford M. The Meta-Analytical Fixers: An Ivermectin Tale; 2021. Available at: https://roundingtheearth. Accessed July 7, 2021. 4. Neil M, Fenton NE, Bayesian Hypothesis Testing and Hierarchical Modelling of Ivermectin Effectiveness in Treating Covid-19, 2021. Available at: 13140/RG.2.2.19703.75680. 5. Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Asian Pac J Trop Med. 2021;14:266. 6. Elgazzar A, Hany B, Youssef SA, et al. Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic; 2020. Available at: https://www.researchsquare. com/article/rs-100956/v2. Ivermectin, A Reanalysis of the Data To the Editor: Our article entitled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” was recently published in the American Journal of Therapeutics.1 Our article included randomized and observational trial meta-analyses on the efficacy of ivermectin for the prophylaxis and treatment of COVID-19. Recently, the study conducted by Elgazzar et al2 has come under scrutiny with accusations of scientific misconduct. His paper was apparently retracted without his knowledge and without giving him the opportunity to defend these serious claims. This situation is most unfortunate. While this issue is being resolved, we decided to redo the original meta-analyses excluding this study. The summary point estimates were largely unaffected when the study by Elgazzar et al was removed. The revised forest plots are provided below (Figures 1–3). FIGURE 1. Meta-analysis of ivermectin prophylaxis trials in COVID-19. Symbols: Squares indicate treatment effect of an individual study. Large diamond reflects summary of study design immediately above. Size of each symbol correlates with the size of the CI around the point estimate of treatment effect with larger sizes indicating a more precise CI. CI, confidence interval; OBS, observational study; RCT, randomized controlled trial. American Journal of Therapeutics (2021) 28(5) Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. e580 Letters to the Editor FIGURE 2. Meta-analysis of the outcome of time to clinical recovery from controlled trials of ivermectin treatment in COVID19. Symbols: Squares indicate treatment effect of an individual study. Large diamond reflects summary of study design immediately above. Small diamond indicates sum effect of all trial designs. Size of each symbol correlates with the size of the CI around the point estimate of treatment effect with larger sizes indicating a more precise CI. CI, confidence interval. FIGURE 3. Meta-analysis of the..
{ 'DOI': '10.1097/mjt.0000000000001443', 'ISSN': ['1075-2765'], 'URL': '', 'author': [ { 'affiliation': [{'name': 'Eastern Virginia Medical School, Norfolk, VA'}], 'family': 'Marik', 'given': 'Paul E.', 'sequence': 'first'}, { 'ORCID': '', 'affiliation': [{'name': 'Front Line Covid 19 Critical Care Alliance, Madison, WI'}], 'authenticated-orcid': False, 'family': 'Kory', 'given': 'Pierre', 'sequence': 'additional'}], 'container-title': 'American Journal of Therapeutics', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 9, 7]], 'date-time': '2021-09-07T20:00:36Z', 'timestamp': 1631044836000}, 'deposited': { 'date-parts': [[2023, 9, 17]], 'date-time': '2023-09-17T04:18:52Z', 'timestamp': 1694924332000}, 'indexed': {'date-parts': [[2024, 3, 8]], 'date-time': '2024-03-08T12:30:46Z', 'timestamp': 1709901046798}, 'is-referenced-by-count': 7, 'issue': '5', 'issued': {'date-parts': [[2021, 9]]}, 'journal-issue': {'issue': '5', 'published-online': {'date-parts': [[2021]]}}, 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '276', 'original-title': [], 'page': 'e579-e580', 'prefix': '10.1097', 'published': {'date-parts': [[2021, 9]]}, 'published-online': {'date-parts': [[2021, 9]]}, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'reference': [ { 'DOI': '10.1097/MJT.0000000000001377', 'article-title': 'Review of the emerging evidence demonstrating the efficacy of ' 'ivermectin in the prophylaxis and treatment of COVID-19', 'author': 'Kory', 'doi-asserted-by': 'crossref', 'first-page': 'e299', 'journal-title': 'Am J Ther.', 'key': 'R1-20230917', 'volume': '28', 'year': '2020'}, { 'article-title': 'Efficacy and safety of ivermectin for treatment and prophylaxis of ' 'COVID-19 pandemic', 'author': 'Elgazzar', 'journal-title': 'Research Square.', 'key': 'R2-20230917', 'year': '2020'}], 'reference-count': 2, 'references-count': 2, 'relation': {}, 'resource': {'primary': {'URL': ''}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Ivermectin, A Reanalysis of the Data', 'type': 'journal-article', 'volume': '28'}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop